Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
Dyne Therapeutics announced management's participation in a fireside chat at the Jefferies Global Healthcare Conference on June 9, 2022, at 3:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dyne Therapeutics announced management's participation in a fireside chat at the Jefferies Global Healthcare Conference on June 9, 2022, at 3:00 p.m. ET. This event will be held in New York, NY, and a live webcast will be accessible via the company’s website. Additionally, a replay will be available for 90 days post-event. Dyne Therapeutics focuses on developing life-transforming therapeutics for genetically driven muscle diseases using its proprietary FORCE™ platform.
Details
News Market Reaction – DYN
The recorded move for DYN in the trading session of this news was +5.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 9, 2022 at 3:00 p.m. ET.
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.
About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of programs for serious muscle diseases, including candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.
Contact:
Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.